Merck & Co., Inc.
Close on Oct 30, 2026Market cap $368.89BP/E 119.6Yield 2.19%
Merck Delstrigo (doravirine/lamivudine/tenofovir disoproxil by Year
Delstrigo (doravirine/lamivudine/tenofovir disoproxil fumarate — HIV-1) — U.S. sales ($M) ($M)
Merck Delstrigo (doravirine/lamivudine/tenofovir disoproxil: $56M in FY2025, unchanged from a year earlier.
Where the FY2025 figure comes from
“|| Delstrigo | 306 | 249 | 23 | 56 | 56 | 1 | 250 | 193 | 29”
Source: Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
Reported in Form 10-Q / 10-K Segment & Product Sales Footnote & Form 8-K Table 3 / 3a / 3b.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Delstrigo (doravirine/lamivudine/tenofovir disoproxil fumarate — HIV-1) — U.S. sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 56 | 0.0% | Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗ |
| FY2024 | Dec 31, 2024 | 56 | +14.3% | Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗ |
| FY2023 | Dec 31, 2023 | 49 | +25.6% | Form 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗ |
| FY2022 | Dec 31, 2022 | 39 | – | Form 10-K (filed 2025-02-25) ↗ |
Breakdown
What makes up delstrigo (doravirine/lamivudine/tenofovir disoproxil
Cite this data
StockData. (2026). Merck Delstrigo (doravirine/lamivudine/tenofovir disoproxil ($M), annual FY2022–FY2025 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev-delstrigo-us
See every metric in the Merck KPI table. Data updated Oct 26, 2026.